Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital

South African Journal of Psychiatry

 
 
Field Value
 
Title Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital
 
Creator Anozie, Ihechiluru G. James, Bawo O. Omoaregba, Joyce O. Oriji, Sunday O. Erohubie, Paul O. Enebe, Anthony C.
 
Subject psychiatry high dose; antipsychotics; prescription; schizophrenia; Nigeria
Description Background: Treatment guidelines recommend the use of antipsychotic monotherapy at effective doses for the treatment of schizophrenia, although about a third of the sufferers still receive high-dose antipsychotic treatment. Current evidence suggests that high-dose antipsychotic prescription (HDAP) not only fails to improve outcomes but also increases side effects.Aim: Our study aimed to determine the prevalence of HDAP and its association with illness severity, medication adherence behaviour and side effects amongst outpatients with schizophrenia.Setting: The Federal Neuro-Psychiatric Hospital, Benin-City, Nigeria.Methods: A cross-sectional study of 320 attendees with schizophrenia at the outpatient department was undertaken. We administered a sociodemographic and antipsychotic medication questionnaire, Mini-International Neuropsychiatric Interview, Positive and Negative Syndrome Scale, Liverpool University Neuroleptic Side Effects Rating Scales and Medication Adherence Rating Scales. High-dose antipsychotic prescription was determined by the ratio of prescribed daily dose to defined daily dose greater than 1.5.Results: The prevalence of HDAP was 38.4%. Greater severity of illness, experiencing more side effects and poor medication adherence were significantly associated with HDAP. The major predictors of HDAP were antipsychotic polypharmacy and concurrent anticholinergic use.Conclusion: We conclude that although the use of HDAP amongst patients with schizophrenia remains common, its persistent use should be discouraged.
 
Publisher AOSIS
 
Contributor
Date 2022-04-29
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — cross-sectional
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajpsychiatry.v28i0.1791
 
Source South African Journal of Psychiatry; Vol 28 (2022); 8 pages 2078-6786 1608-9685
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajp.org.za/index.php/sajp/article/view/1791/2618 https://sajp.org.za/index.php/sajp/article/view/1791/2619 https://sajp.org.za/index.php/sajp/article/view/1791/2620 https://sajp.org.za/index.php/sajp/article/view/1791/2621
 
Coverage Africa; Europe; United Kingdom, America — Age; gender; adult; antipsychotics; high dose; schizophrenia;
Rights Copyright (c) 2022 Ihechiluru G. Anozie, Bawo O. James, Joyce O. Omoaregba, Sunday O. Oriji, Paul O. Erohubie, Anthony C. Enebe https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT